Cargando…

A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline

OBJECTIVE: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) represents an attractive target for tumor diagnosis agents. Previously, radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) was reported to possess good characteristics as a tumor imaging agent. We have explored the fea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Masahiko, Kanai, Yasukazu, Naka, Sadahiro, Yoshimoto, Mitsuyoshi, Kagawa, Shinya, Matsumuro, Keiji, Katsuma, Hideyuki, Yamaguchi, Hiroshi, Magata, Yasuhiro, Ohmomo, Yoshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672506/
https://www.ncbi.nlm.nih.gov/pubmed/23494210
http://dx.doi.org/10.1007/s12149-013-0703-y
_version_ 1782272112884449280
author Hirata, Masahiko
Kanai, Yasukazu
Naka, Sadahiro
Yoshimoto, Mitsuyoshi
Kagawa, Shinya
Matsumuro, Keiji
Katsuma, Hideyuki
Yamaguchi, Hiroshi
Magata, Yasuhiro
Ohmomo, Yoshiro
author_facet Hirata, Masahiko
Kanai, Yasukazu
Naka, Sadahiro
Yoshimoto, Mitsuyoshi
Kagawa, Shinya
Matsumuro, Keiji
Katsuma, Hideyuki
Yamaguchi, Hiroshi
Magata, Yasuhiro
Ohmomo, Yoshiro
author_sort Hirata, Masahiko
collection PubMed
description OBJECTIVE: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) represents an attractive target for tumor diagnosis agents. Previously, radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) was reported to possess good characteristics as a tumor imaging agent. We have explored the feasibility of developing tumor diagnosis ligands superior to radioiodinated PHY. METHODS: New phenoxyquinazoline derivatives were designed with various side chains introduced to the 6th position of PHY. The IC(50) values of the new derivatives to interrupt EGFR-TK phosphorylation were evaluated and compared to well-known EGFR-TK inhibitors. Tumor uptake studies of the new (125)I-labeled derivatives were conducted with A431 tumor-bearing mice. Selectivity and binding characteristics were analyzed by in vitro blocking studies and a binding assay. Furthermore, SPECT/CT scans were performed using A431 tumor-bearing mice. RESULTS: Six quinazoline derivatives were designed and synthesized, and among these, 6a–d were found to have relatively high EGFR-TK inhibitory potency. In tumor uptake studies, [(125)I]6a ([(125)I]PYK) was found to have the highest tumor uptake and longest retention in tumors. In contrast, [(125)I]PYK was rapidly cleared from peripheral tissues, resulting in a high tumor-to-tissue ratio 24 h after injection. Moreover, the EGFR-TK selectivity of [(125)I]PYK was confirmed by pretreatment experiments with specific EGFR-TK inhibitors. Furthermore, [(125)I]PYK provided clear SPECT images of tumors. CONCLUSIONS: Radioiodinated PYK, one of the newly synthesized quinazoline derivatives, was found to be a desirable ligand for EGFR-TK SPECT imaging. [(125)I]PYK showed high tumor accumulation and selective EGFR-TK binding and also succeeded in delivering high contrast imaging of tumors. These favorable characteristics of [(125)I]PYK suggest that the (123)I-labeled counterpart, [(123)I]PYK, would have great potential for diagnostic SPECT tumor imaging.
format Online
Article
Text
id pubmed-3672506
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-36725062013-06-10 A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline Hirata, Masahiko Kanai, Yasukazu Naka, Sadahiro Yoshimoto, Mitsuyoshi Kagawa, Shinya Matsumuro, Keiji Katsuma, Hideyuki Yamaguchi, Hiroshi Magata, Yasuhiro Ohmomo, Yoshiro Ann Nucl Med Original Article OBJECTIVE: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) represents an attractive target for tumor diagnosis agents. Previously, radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) was reported to possess good characteristics as a tumor imaging agent. We have explored the feasibility of developing tumor diagnosis ligands superior to radioiodinated PHY. METHODS: New phenoxyquinazoline derivatives were designed with various side chains introduced to the 6th position of PHY. The IC(50) values of the new derivatives to interrupt EGFR-TK phosphorylation were evaluated and compared to well-known EGFR-TK inhibitors. Tumor uptake studies of the new (125)I-labeled derivatives were conducted with A431 tumor-bearing mice. Selectivity and binding characteristics were analyzed by in vitro blocking studies and a binding assay. Furthermore, SPECT/CT scans were performed using A431 tumor-bearing mice. RESULTS: Six quinazoline derivatives were designed and synthesized, and among these, 6a–d were found to have relatively high EGFR-TK inhibitory potency. In tumor uptake studies, [(125)I]6a ([(125)I]PYK) was found to have the highest tumor uptake and longest retention in tumors. In contrast, [(125)I]PYK was rapidly cleared from peripheral tissues, resulting in a high tumor-to-tissue ratio 24 h after injection. Moreover, the EGFR-TK selectivity of [(125)I]PYK was confirmed by pretreatment experiments with specific EGFR-TK inhibitors. Furthermore, [(125)I]PYK provided clear SPECT images of tumors. CONCLUSIONS: Radioiodinated PYK, one of the newly synthesized quinazoline derivatives, was found to be a desirable ligand for EGFR-TK SPECT imaging. [(125)I]PYK showed high tumor accumulation and selective EGFR-TK binding and also succeeded in delivering high contrast imaging of tumors. These favorable characteristics of [(125)I]PYK suggest that the (123)I-labeled counterpart, [(123)I]PYK, would have great potential for diagnostic SPECT tumor imaging. Springer Japan 2013-03-15 2013 /pmc/articles/PMC3672506/ /pubmed/23494210 http://dx.doi.org/10.1007/s12149-013-0703-y Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Hirata, Masahiko
Kanai, Yasukazu
Naka, Sadahiro
Yoshimoto, Mitsuyoshi
Kagawa, Shinya
Matsumuro, Keiji
Katsuma, Hideyuki
Yamaguchi, Hiroshi
Magata, Yasuhiro
Ohmomo, Yoshiro
A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
title A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
title_full A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
title_fullStr A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
title_full_unstemmed A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
title_short A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
title_sort useful egfr-tk ligand for tumor diagnosis with spect: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3′-iodophenoxy)quinazoline
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672506/
https://www.ncbi.nlm.nih.gov/pubmed/23494210
http://dx.doi.org/10.1007/s12149-013-0703-y
work_keys_str_mv AT hiratamasahiko ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT kanaiyasukazu ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT nakasadahiro ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT yoshimotomitsuyoshi ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT kagawashinya ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT matsumurokeiji ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT katsumahideyuki ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT yamaguchihiroshi ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT magatayasuhiro ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT ohmomoyoshiro ausefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT hiratamasahiko usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT kanaiyasukazu usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT nakasadahiro usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT yoshimotomitsuyoshi usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT kagawashinya usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT matsumurokeiji usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT katsumahideyuki usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT yamaguchihiroshi usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT magatayasuhiro usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline
AT ohmomoyoshiro usefulegfrtkligandfortumordiagnosiswithspectdevelopmentofradioiodinated63morpholinopropoxy7ethoxy43iodophenoxyquinazoline